Faculty Collaboration Database

Epigenetic Therapy in a Patient With Down Syndrome and Refractory Acute Myeloid Leukemia. J Pediatr Hematol Oncol 2019 Jan;41(1):e38-e40

Date

04/19/2018

Pubmed ID

29668549

DOI

10.1097/MPH.0000000000001158

Scopus ID

2-s2.0-85046027326 (requires institutional sign-in at Scopus site)   12 Citations

Abstract

Acute myeloid leukemia (AML) associated with Down syndrome (DS-AML) is a unique entity of AML with superior treatment response and overall survival compared with children with non-DS-AML. Despite good outcomes in DS-AML, those who relapse or have refractory disease have poor survival. Successful treatment of these patients is challenged by increased incidence of treatment-related toxicities often encountered with high-dose chemotherapy. Here we report the experience of epigenetic modifying agents (decitabine and vorinostat) followed by fludarabine, cytarabine, and granulocyte colony stimulating growth factor for a child with refractory DS-AML. This combination was well tolerated and resulted in a brief clinical response.

Author List

Becktell K, Houser K, Burke MJ

Authors

Kerri Becktell MD Assistant Professor in the Pediatrics department at Medical College of Wisconsin
Michael James Burke MD Professor in the Pediatrics department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Antineoplastic Combined Chemotherapy Protocols
Cytarabine
Down Syndrome
Granulocyte Colony-Stimulating Factor
Humans
Infant
Leukemia, Myeloid, Acute
Male
Vidarabine